Stockscreener 앱 받기
5.65
2.25%
-0.13
전일 마감가:
$5.78
열려 있는:
$5.8
하루 거래량:
24,516
Relative Volume:
0.48
시가총액:
$175.92M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-2.0324
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
+1.62%
1개월 성능:
-15.80%
6개월 성능:
-22.92%
1년 성능:
+29.89%
1일 변동 폭
$5.65
$5.88
1주일 범위
$5.36
$6.00
52주 변동 폭
$3.19
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
5.65 | 175.92M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 6.3% in December - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(ACRV) On The My Stocks Page - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Growth in Short Interest - MarketBeat
Geode Capital Management LLC Has $2.12 Million Stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Investment Report - Stock Traders Daily
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
State Street Corp Acquires 47,233 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Brokerages - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Sells 27,705 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential By Investing.com - Investing.com Nigeria
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential - Investing.com India
(ACRV) Technical Data - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ACRV Earnings - MarketBeat
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Simply Wall St
Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright - Defense World
BMO Capital Markets Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $27.00 - Defense World
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results - TipRanks
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright - MarketBeat
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position | ACRV Stock News - StockTitan
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Average PT from Analysts - Defense World
Trend Tracker for (ACRV) - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com Canada
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa
(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ACRV) Investment Analysis and Advice - Stock Traders Daily
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):